Clearbridge Investments LLC Sells 43,345 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Clearbridge Investments LLC cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,686,384 shares of the biopharmaceutical company's stock after selling 43,345 shares during the quarter. Clearbridge Investments LLC owned 1.59% of Intra-Cellular Therapies worth $140,847,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC boosted its stake in shares of Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after buying an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC grew its holdings in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after acquiring an additional 8,440 shares during the period. Principal Financial Group Inc. increased its position in Intra-Cellular Therapies by 3.3% during the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock valued at $43,735,000 after acquiring an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC bought a new position in Intra-Cellular Therapies in the fourth quarter valued at about $206,000. 92.33% of the stock is owned by institutional investors.

Remove Ads

Intra-Cellular Therapies Price Performance

NASDAQ ITCI remained flat at $131.87 during trading hours on Friday. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock has a 50 day moving average price of $129.53 and a two-hundred day moving average price of $101.03.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Eleven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.